{'fraction_non_alphanumeric': 0.030026109660574413, 'fraction_numerical': 0.010443864229765013, 'mean_word_length': 5.087301587301587, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Mast Cells and KIT as Potential Therapeutic Targets in Severe Asthma.

Mast cells and many of their secreted products have long been thought to contribute to the pathologic processes underlying asthma,1,2 but no clinical studies have assessed whether specifically targeting mast-cell survival or development would have therapeutic benefit in the treatment of this disorder. In this issue of the Journal, Cahill and colleagues3 report the results of a randomized, double-blind, placebo-controlled, phase 2, 24-week, proof-of-principle trial in which patients with severe, poorly controlled asthma were treated with the tyrosine kinase inhibitor imatinib, which can inhibit KIT,4 the major survival and growth factor for mast cells.2 The total number of patients . . .